No abstract

The aim of this study was to improve the dissolution rate of the poorly soluble drug Clofibrate by delivering the drug as a liquisolid compact. Liquisolid compacts were prepared using propylene glycol as solvent, microcrystalline cellulose as carrier, Starch, Silica and Lactose are used as coating materials. Sodium starch glycolate and Cross carmellose sodium are used as a Super disintigrants. The crystallinity of the newly formulated drug and the interaction between excipients was examined by X-ray powder diffraction and Fouriertransform infrared spectroscopy, respectively. The dissolution studies for the liquisolid formulation and the Conventional tablet were carried out at a pH 6.8 buffer. The results showed no change in the crystallinity of the drug and no interaction between excipients. The dissolution efficiency of Clofibrate at 60 min was increased from 71.02% for plain drug and 81.3% for Conventional Tablet to 100.47% for the liquisolid formulation. The increase in the dissolution rate was also found to be significant compared to the pure drug and Conventional Tablet at pH 6.8 buffer. The liquisolid technique appears to be a promising approach for improving the dissolution of poorly soluble drugs like Clofibrate.

Present review highlights the potential of nasal mucosa as an administration route for targeting the central nervous system, the brain. Targeted drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of medication in the remaining tissues. Thus improving efficacy of the drug and reducing side effects. The nasal mucosa when compared to other mucous membranes is easily accessible and provides a practical entrance portal for small and large molecules. Intranasal administration offers rapid onset of action, no first-pass effect, no gastrointestinal degradation or lung toxicity and non-invasiveness application and also improves bioavailability. It is thought that olfactory route of drug transport, by pass the blood-brain barrier and allows the direct transport of drug from the nose to the brain. This review provides an overview of strategies to improve the drug delivery to brain via nasal mucosa and recent advances in this field.

The objective of the present study was to prepare nanofibers of Lornoxicam by Electro spinning technique and to increase the drug bioavailability using different polymers such as PMMA, Ethyl Cellulose, Polyethylene oxide, Gelatin. Totally 15 different formulations of Lornoxicam were prepared by Electro spinning technique and prepared nanofibers are evaluated for various characteristics like drug content, in-vitro release studies, DSC, XRD and SEM studies. The dissolution profile of optimized formulation was compared with that of the API and the marketed product (Lofecam) and the Optimized formulation (F15) exhibited similar dissolution profiles as that of innovator brand. The drug release from the optimized formulation (F15) was slow and extended over a period of 8hrs and these nanofibers were found to be suitable for the oral controlled release formulation. The Optimized formulation (F15) followed First-order release kinetics as it showed highest linearity (r 2 =0.952).

Aim: The present study revolved around determining the effect of increase in the solubility of these drugs at the absorption site using ritonavir as a drug model. Materials & methods: Ritonavir per-oral tablets were prepared using versatile and nonionic surfactants having high solubilization rate, which were further marked with high rate of dissolution. The high rate of dissolution formula applied to the solid state characterization by means of transition electron microscopy, differential scanning calorimetry, scanning electron microscopy, X-ray diffraction and infrared spectroscopy. Results & conclusion: The drug bioavailability was seen to increase expressively by administration of liquisolid tablets as compared with conventional tablets.